Novartis Japan unit charged over research manipulation

July 1, 2014

Japanese prosecutors Tuesday laid charges against the local unit of Swiss pharmaceutical giant Novartis in a widening scandal over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure drug.

Prosecutors also indicted former employee Nobuo Shirahashi, 63, alleging he manipulated the data in clinical studies that were later used in marketing the drug Valsartan.

The dual charges laid by the Tokyo District Public Prosecutor's Office—which allege that Novartis bore responsibility for Shirahashi's actions—came several weeks after he was first arrested and authorities raided the offices of Novartis Pharma KK in the Japanese capital.

The drug studies suggested Valsartan—sold under the brand name Diovan in Japan, and licensed for use in more than 100 countries—could help prevent strokes and angina, in addition to its acknowledged benefits in combating .

The firm used data from those studies to market its , playing up its supposed additional benefits.

"We take the arrest of our former employee and the indictment of our company very seriously," the unit said in a statement on its website.

"We deeply apologise to patients, their families and medical workers as well as Japanese people for causing these concerns and trouble," it added.

The 's Japan unit has also been embroiled in another scandal over allegations it did not properly disclose the possible side effects of leukaemia treatments.

In April, Novartis replaced the top executives at its Japanese arm over those allegations.

Under the country's pharmaceutical law, anyone found guilty of exaggerating advertising can face up to two years in prison or a fine of as much as two million yen ($19,000).

Explore further: Japan prosecutors arrest ex-Novartis employee over data

Related Stories

Japan prosecutors arrest ex-Novartis employee over data

June 11, 2014
Prosecutors on Wednesday arrested a former employee of the Japanese unit of Swiss pharmaceutical giant Novartis for allegedly manipulating research data to exaggerate the benefits of a popular blood-pressure drug.

Japan prosecutors raid Novartis over drug ad scandal

February 19, 2014
Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Japan files criminal complaint against Novartis arm

January 9, 2014
Japan's health ministry on Thursday filed a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, the company said.

Novartis' top Japan executives quit over cancer drug scandal (Update)

April 3, 2014
Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators.

Japan to seek criminal prosecution of Novartis

December 18, 2013
Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.

Japan university reveals more claims of fabricated drug data

July 31, 2013
A Japanese university Wednesday said it would retract a study that touted the effectiveness of a blood pressure drug made by Swiss pharmaceutical giant Novartis because it was based on fabricated data.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.